AFT PHARMACEUTICALS LIMITED — Director's Dealing 2017

Jun 18, 2017

==> picture [109 x 26] intentionally omitted <==

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

ToNZX Limited; and		AFT Pharmaceuticals Limited(AFT) 19-Jun-17 22-Dec-15 David Flacks AFT Pharmaceuticals Limited(AFT) Not applicable Director Fully-Paid OrdinaryShares in AFT Joint registered holder and beneficial owner of ordinary shares 83,764 115,431 David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata Family Trust David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata Family Trust 2 1. 16-Jun-17 2. 15-Jun-17 1. Allotment of new ordinary shares pursuant to Share Purchase Plan 2. On-Market acquisition of ordinaryshares 1. Not applicable 2. Unknown 1. NZ$2.25 per share 2. NZ$2.30per share 1. 6,667 2. 25,000 No Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable	AFT Pharmaceuticals Limited(AFT) 19-Jun-17 22-Dec-15 David Flacks AFT Pharmaceuticals Limited(AFT) Not applicable Director Fully-Paid OrdinaryShares in AFT Joint registered holder and beneficial owner of ordinary shares 83,764 115,431 David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata Family Trust David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata Family Trust 2 1. 16-Jun-17 2. 15-Jun-17 1. Allotment of new ordinary shares pursuant to Share Purchase Plan 2. On-Market acquisition of ordinaryshares 1. Not applicable 2. Unknown 1. NZ$2.25 per share 2. NZ$2.30per share 1. 6,667 2. 25,000 No Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
Name of listedissuer:
Date this disclosuremade:
Date of last disclosure:
Directororsenior managergiving disclosure
Full name(s):
Name of listedissuer:
Name of related body corporate (ifapplicable):
Position heldin listedissuer:
Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Class ofaffected quotedfinancialproducts:
Class ofaffected quotedfinancialproducts:		Fully-Paid OrdinaryShares in AFT
Nature of the affected relevant interest(s):		Joint registered holder and beneficial owner of ordinary shares
For that relevant interest-
Number held in class before acquisition or disposal:		83,764
Number held in class after acquisition or disposal:		115,431
Current registered holder(s):		David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata Family Trust
Registered holder(s) once transfers are registered:		David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata Family Trust
Details of transactions giving rise to acquisition or disposal
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:		2
Date of transaction:
Nature of transaction:
Name of anyotherpartyorparties to the transaction(if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value,describe the consideration:
Number of financialproducts to which the transaction related:
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include thefollowing details—
Whether relevant interests were acquired or disposed of duringa closedperiod:		No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:		Not applicable
Date ofthe prior writtenclearance (ifany):		Not applicable
Summary of other relevant interests after acquisition or disposal: Class ofquoted financialproducts: Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative: Details of derivative,-
		Not applicable
The notional value of the derivative (if any) or the notional amount of underlying financial products (ifany):		Not applicable
Astatement as towhetherthe derivativeis cashsettled orphysically settled:		Not applicable
Maturity date ofthe derivative (ifany):		Not applicable
Expiry date ofthe derivative (ifany):		Not applicable
The price's specified terms (ifany):		Not applicable
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financialproducts:		Not applicable
_For that derivative relevant interest,- _
Parties to the derivative:		Not applicable

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Not applicable

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:

==> picture [47 x 56] intentionally omitted <==

19-Jun-17

==> picture [490 x 48] intentionally omitted <==